Hypothesis: glutaminyl cyclase inhibitors decrease risks of Alzheimer's disease and related dementias.
Charles H Hennekens1, Benjamin A Bensadon1, Robert Zivin2,3
1a 1 Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, Building 71, Suite 337, Boca Raton, FL 33431, USA.
Expert Review of Neurotherapeutics
|October 10, 2015
Summary
Glutaminyl cyclase (QC) inhibitors show early promise for Alzheimer's disease and related dementias (ADRD). Further large-scale trials are needed to confirm the efficacy and safety of QC inhibitors for treating these progressive neurodegenerative disorders.
Area of Science:
- Neurodegenerative diseases
- Amyloidosis
- Gerontology
Background:
- Alzheimer's disease and related dementias (ADRD) are progressive, incurable neurodegenerative disorders.
- The prevalence of sporadic ADRD is rising globally due to an aging population.
- ADRD impose significant societal and economic burdens comparable to cardiovascular disease and cancer.
Purpose of the Study:
- To evaluate the potential of glutaminyl cyclase (QC) inhibitors in managing ADRD.
- To address the current lack of evidence for effective pharmacologic treatments for ADRD.
- To highlight the need for rigorous clinical trials to validate novel therapeutic approaches.
Main Methods:
- Review of existing evidence on glutaminyl cyclase (QC) inhibitors.
- Assessment of safety profiles of QC inhibitors.
- Identification of requirements for future clinical studies.
Main Results:
- Glutaminyl cyclase (QC) inhibitors have demonstrated early, potential efficacy in preliminary studies.
- QC inhibitors exhibit a reassuring safety profile.
- Current evidence is insufficient to establish definitive efficacy and safety for ADRD treatment.
Conclusions:
- Glutaminyl cyclase (QC) inhibitors represent a promising therapeutic avenue for ADRD.
- Large-scale, randomized controlled trials are essential to confirm the efficacy and safety of QC inhibitors.
- Further research is critical to develop effective treatments for the growing ADRD population.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
847
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
847
01:14Antiepileptic Drugs: Glutamate Antagonists
1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K
01:26Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
870
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
870